

Curriculum vitae del Prof. Nicola Fazio

Education and PHD/Masters/Courses

- July 1988: **Degree in Medicine and Surgery**, University of L'Aquila
- November 1988: Qualification to practice medicine
- 1993: **Specialization in Internal Medicine**, University of L'Aquila
- 2002: **Specialization in Oncology**, Statal University of Milan
- 2011: **PhD in Digestive Oncology**, University "La Sapienza", Rome

Titles (included other positions covered)

- **2024-2025 ENETS President elect**
- Since 2020: Member of the ENETS (European Society of Neuroendocrine Tumors) Executive Committee
- Since 2020: Member of the Steering Committee of SPARC (Stakeholder Political Alliance For Radioligand Cancer Therapies)
- Since 2020: Member of the ESMO Faculty for NETs, endocrine tumors and CUP
- Since 2017: Member of the ESMO "Gastrointestinal tumors" Faculty
- 2000: Advanced **Diploma in Neuroendocrine Tumors**, Department of Endocrine Oncology (Prof Kjell Oberg), University Hospital, Uppsala, Sweden

Academic titles and activities

- 2017-2023: Qualification as Associate Professor, Oncology
- Since 2017: **Contract Professor** – Internal Medicine, critical area, 3th year of Nurse Degree – Statal University of Milan
- 2019-2030: Qualification as Full Professor, Oncology
- 2006-2014 – **Teaching at Master of 1st level in palliative care** - University of Milan, Faculty of Medicine and Surgery - Prof Bruno Andreoni
- Since 1997: Co-adjudicator of > 10 degree and specialization theses at several Universities across Italy, mainly Milan.

Clinical Activities carried out at IEO

- **Since Apr 2018: Director of Program of Digestive and Neuroendocrine Tumors**
- **Since Oct 2017: Director of the Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors**
- **Since 2015: Head of the ENETS Center of Excellence for GEP NETs**
- May 2017 - Feb 2018: Vice Director of Program of Digestive and Neuroendocrine Tumors Apr 2013
- Sep 2017: Director of the Unit of Gastrointestinal Medical Oncology and Neuroendocrine Tumors
- Jul 2011 – Mar 2013: Director of the Unit of Upper Gastrointestinal Medical and Neuroendocrine Tumors
- Jul 2008 – Jun 2011: Senior Vice Director, Division of Medical Oncology
- Apr 2004 – Jun 2008: Vice Director, Division of Medical Oncology
- Jun 2003 - Mar 2004: Senior Assistant, Division of Medical Oncology
- Jun 1998 – May 2003: Assistant, Division of Medical Oncology
- Jun 1996 - May 1998: Fellow, Division of Medical Oncology
- Oct 1995 – May 1996: Unpaid physician, Division of Medical Oncology

Research Activities carried out at IEO

- 1993-1995: Responsible physician of a Center of Neuromotor Rehabilitation, "Fisiomedica Loretana", Toro (CB)
- 1990 – 1993: Internal Medicine consultant at "Fisiomedica Loretana", Toro (CB)
- 1991 – 1993: Theoretical-practical training in General Medicine (in accordance with Interministerial Decree of 10/10/88)
- 1989 – 1991: Unpaid physician at "Cardarelli" Regional Hospital in Campobasso, Division of Internal Medicine
- 1990 – 1996: USL Centro Molise, Campobasso, Italy – First aid and emergency services for local Health Authority
- 1989 – 1995: USL Centro Molise, Campobasso, Italy – Locum General Practitioner
- 1988: Unpaid physician at the Division of Internal Medicine, Pol. "Careggi", Florence, Director Prof Neri Serneri

Passed Clinical and Research Activities

- 2019 – 2020: **Chairman of the ENETS Advisory Board**
- 2013 – 2019: **National coordinator of AIOM NEN guidelines**
- 2019 – 2020: Member of the ITANET Scientific Committee
- 2016 – 2019: **Coordinator of the ESMO Faculty for "Neuroendocrine, Endocrine neoplasms and CUP"**
- Dal 2013: **Scientific and organizational responsible of the annual course ESMO NEN Preceptorship**
- 2019: Scientific and organizational responsible **of the ESMO NEN Advanced Course**
- 2015 – 2018: Member of the ENETS Advisory Board
- 2014 – 2018: Member of the ITANET Executive Committee
- Since 2013: **Scientific and organizational responsible of the IEO NEN annual Preceptorship**

Grants

- 2024: PNRR: M6/C2_CALL 2023, PNRR-TR1-2023-12378370 – Sezione “Tumori rari” – P.I. of the project: “EpigenOMIC determinants of the neuroendocrine phenotype as biomarkers for noninvasive diagnosis of neuroendocrine neoplasms” selected for PNRR grant (1.000.000,00 €).
- 2019: P.I. of the project entitled “Efficacy of cabozantinib in preclinical model of neuroendocrine neoplasms” – Selected for an Ipsen global grant (50.000 €).

Selected articles from more than 250 in peer-reviewed journals:

1. Gervaso L, Ciardiello D, Oliveira RA, Borghesani M, Guidi L, Benini L, Algeri L, Spada F, Zampino MG, Cella CA, **Fazio N**. Immunotherapy in the neoadjuvant treatment of gastrointestinal tumors: is the time ripe? *J Immunother Cancer*. 2024 May 23;12(5):e008027. doi: 10.1136/jitc-2023-008027.
2. D'Angelo SP, Lebbé C, Mortier L, Brohl AS, **Fazio N**, Grob JJ, Prinzi N, Hanna GJ, Hassel JC, Kiecker F, von Heydebreck A, Güzel G, Nghiem P. First-line avelumab treatment in patients with metastatic Merkel cell carcinoma: 4-year follow-up from part B of the JAVELIN Merkel 200 study. *ESMO Open*. 2024 May;9(5):103461. doi: 10.1016/j.esmoop.2024.103461. Epub 2024 May 13. PMID: 38744102
3. Bertani E, Mattana F, Collamati F, Ferrari ME, Bagnardi V, Frassoni S, Pisa E, Mirabelli R, Morganti S, **Fazio N**, Fumagalli Romario U, Ceci F. Radio-Guided Surgery with a New-Generation β -Probe for Radiolabeled Somatostatin Analog, in Patients with Small Intestinal Neuroendocrine Tumors. *Ann Surg Oncol*. 2024 Jul;31(7):4189-4196. doi: 10.1245/s10434-024-15277-x. Epub 2024 Apr 23. PMID: 38652200
4. Kos-Kudła B, Castaño JP, Denecke T, Grande E, Kjaer A, Koumariou A, de Mestier L, Partelli S, Perren A, Stättner S, Valle JW, **Fazio N**. European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for nonfunctioning pancreatic neuroendocrine tumours. *J Neuroendocrinol*. 2023 Dec;35(12):e13343. doi: 10.1111/jne.13343. Epub 2023 Oct 25. PMID: 37877341
5. La Salvia A, Modica R, Rossi RE, Spada F, Rinzivillo M, Panzuto F, Faggiano A, Cinieri S, **Fazio N**. Targeting neuroendocrine tumors with octreotide and lanreotide: Key points for clinical practice from NET specialists. *Cancer Treat Rev*. 2023 Jun;117:102560. doi: 10.1016/j.ctrv.2023.102560. Epub 2023 Apr 17.
6. Klempner SJ, Lee KW, Shitara K, Metges JP, Lonardi S, Ilson DH, **Fazio N**, Kim TY, Bai LY, Moran D, Yang J, Arozullah A, Park JW, Raizer JJ, Bang YJ, Shah MA. ILLUSTRO: Phase II Multicohort Trial of Zolbetuximab in Patients with Advanced or Metastatic Claudin 18.2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma. *Clin Cancer Res*. 2023 Oct 2;29(19):3882-3891. doi: 10.1158/1078-0432.CCR-23-0204. PMID: 37490286
7. **Fazio N**, La Salvia A. Precision medicine in gastroenteropancreatic neuroendocrine neoplasms: Where are we in 2023? *Best Pract Res Clin Endocrinol Metab*. 2023 Sep;37(5):101794. doi: 10.1016/j.beem.2023.101794. Epub 2023 Jun 28.
8. Sorbye H, Grande E, Pavel M, Tesselaar M, **Fazio N**, Reed NS, Knigge U, Christ E, Ambrosini V, Couvelard A, Tiensuu Janson E. European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for digestive neuroendocrine carcinoma. *J Neuroendocrinol*. 2023 Mar;35(3):e13249. doi: 10.1111/jne.13249. Epub 2023 Mar 16. PMID: 36924180
9. Cella CA, Knoedler M, Hall M, Arcopinto M, Bagnardi V, Gervaso L, Pellicori S, Spada F, Zampino MG, Ravenda PS, Frassoni S, Passaro A, Milano M, Laffi A, **Fazio N**, Lordick F. Validation of the ONKOTEV Risk Prediction Model for Venous Thromboembolism in Outpatients With Cancer. *JAMA Netw Open*. 2023 Feb 1;6(2):e230010. doi: 10.1001/jamanetworkopen.2023.0010. PMID: 36795409; PMCID:PMC9936336.
10. Tiberti S, Catozzi C, Croci O, Ballerini M, Cagnina D, Soriani C, Scirgolea C, Gong Z, He J, Macandog AD, Nabinejad A, Nava Lauson CB, Quinte' A, Bertalot G, Petz WL, Ravenda SP, Licursi V, Paci P, Rasponi M, Rotta L, **Fazio N**, Ren G, Fumagalli-Romario U, Schaefer MH, Campaner S, Lugli E, Nezi L, Manzo T. GZMK T effector memory cells are associated with CD15 neutrophil abundance in non-metastatic colorectal tumors and predict poor clinical outcome. *Nat Commun*. 2022 Nov 8;13(1):6752. doi: 10.1038/s41467-022-34467-3. Erratum in: *Nat Commun*. 2022 Nov 30;13(1):7380. PMID: 36347862; PMCID: PMC9643357.
11. Arrivi G, Spada F, Frassoni S, Bagnardi V, Laffi A, Rubino M, Gervaso L, **Fazio N**. Metronomic chemotherapy in patients with advanced neuroendocrine tumors: A single-center retrospective analysis. *J Neuroendocrinol*. 2022 Oct;34(10):e13189. doi: 10.1111/jne.13189. Epub 2022 Aug 16. PMID: 36306196; PMCID: PMC9786253.
12. **Fazio N**, Maisonneuve P, Spada F, Gervaso L, Cella CA, Pozzari M, Zerini D, Pisa E, Fumagalli C, Barberis M, Laffi A, Grana C CM, Orsolini G, Prestianni P, Bonomo G, Funicelli L, Bertani E, Queirolo P, Ravizza D, Rubino M, Tosti G, Pennacchioli E. Nodal Merkel Cell Carcinoma with Unknown Primary Site and No Distant Metastasis: A Single-Center Series. *Cancers (Basel)*. 2022 Sep 29;14(19):4777. doi: 10.3390/cancers14194777. PMID: 36230698; PMCID: PMC9563944.
13. **Fazio N**, Gervaso L, Halfdanarson TR, La Salvia A, Hofland J, Hernando J, Sonbol MB, Garcia-Carbonero R, Capdevila J, de Herder WW, Koumariou A, Kaltsas G, Rossi M, Grozinsky-Glasberg S, Oleinikov K, Boselli S, Tamayo D, Bagnardi V, Laffi A, Rubino M, Spada F. Coronavirus disease 2019 in patients with neuroendocrine neoplasms: Preliminary results of the INTENSIVE study. *Eur J Cancer*. 2021 Sep;154:246-252. doi: 10.1016/j.ejca.2021.06.029. Epub 2021 Jun 30. Erratum in: *Eur J Cancer*. 2022 Jan;160:289-290. PMID: 34298375; PMCID: PMC8241688.
14. Baudin E, Caplin M, Garcia-Carbonero R, Fazio N, Ferolla P, Filosso PL, Frilling A, de Herder WW, Hörsch D, Knigge U, Korse CM, Lim E, Lombard-Bohas C, Pavel M, Scoazec JY, Sundin A, Berruti A; Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis,

treatment and follow-up☆.ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. *Ann Oncol*. 2021 Apr;32(4):439-451. doi: 10.1016/j.annonc.2021.01.003. Epub 2021 Jan 19. PMID: 33482246

15. **Fazio N**. Personalizing Multimodal Treatment in Patients With Pancreatic Neuroendocrine Tumors. *JCO Oncol Pract* 2020 Nov;16(11):729-730. doi: 10.1200/OP.20.00749.
16. Rubino M , Scoazec JY , Pisa E , M, Spaggiari L , Hadoux J , Spada F , Planchard D , Cella CA , Leboulleux S , De Marinis F , Ducreux M , Lamartina L , Baudin E , **Fazio N**. Lung carcinoids with high proliferative activity: Further support for the identification of a new tumor category in the classification of lung neuroendocrine neoplasms. *Lung Cancer* 2020 Oct; 148:149-158. doi: 10.1016/j.
17. Van Cutsem E, Tempero MA, Sigal D, Oh DY, **Fazio N**, Macarulla T, Hitre E, Hammel P, Hendifar AE, Bates SE, Li CP, Hingorani SR, de la Fouchardiere C, Kasi A, Heinemann V, Maraveyas A, Bahary N, Layos L, Sahai V, Zheng L, Lacy J, Park JO, Portales F, Oberstein P, Wu W, Chondros D, Bullock AJ; HALO 109-301 Investigators. Randomized Phase III Trial of Pegvorhialuronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma. *J Clin Oncol*. 2020 Jul 24;JCO2000590. doi: 10.1200/JCO.20.00590. Epub ahead of print. PMID: 32706635.
18. Spada F, Maisonneuve P, Fumagalli C, Marconcini R, Gelsomino F, Antonuzzo L, Campana D, Puliafito I, Rossi G, Faviana P, Messerini L, Barberis M, **Fazio N**. Temozolomide alone or in combination with capecitabine in patients with advanced neuroendocrine neoplasms: an Italian multicenter real-world analysis. *Endocrine*. 2020 Jul 22. doi: 10.1007/s12020-020-02421-2. Epub ahead of print. PMID: 32700133.
19. **Fazio N**. Cisplatin Plus Gemcitabine as Standard of Care for Germline *BRCA/PALB2*-Mutated Pancreatic Adenocarcinoma: Are We Moving Too Fast? *J Clin Oncol*. 2020 Jul 20;38(21):2466-2467. doi: 10.1200/JCO.20.00419. Epub 2020 May 14. PMID: 32407212.
20. **Fazio N**, Cella CA, Del Re M, Laffi A, Rubino M, Zagami P, Spada F. Pharmacodynamics, clinical findings and approval status of current and emerging tyrosine-kinase inhibitors for pancreatic neuroendocrine tumors. *Expert Opin Drug Metab Toxicol*. 2019 Dec;15(12):993-1004. doi: 10.1080/17425255.2019.1700951. Epub 2019 Dec 12. PMID: 31794273.
21. **Fazio N**, Martini JF, Croitoru AE, Schenker M, Li S, Rosbrook B, Fernandez K, Tomasek J, Thiis-Evensen E, Kulke M, Raymond E. Pharmacogenomic analyses of sunitinib in patients with pancreatic neuroendocrine tumors. *Future Oncol*. 2019 Jun;15(17):1997-2007. doi: 10.2217/fon-2018-0934. Epub 2019 May 14. PMID:31084373.
22. Yao J, Garg A, Chen D, Capdevila J, Engstrom P, Pommier R, Van Cutsem E, Singh S, **Fazio N**, He W, Riester M, Patel P, Voi M, Morrissey M, Pavel M, Kulke MH. Genomic profiling of NETs: a comprehensive analysis of the RADIANT trials. *Endocr Relat Cancer*. 2019 Apr 1;26(4):391-403. doi: 10.1530/ERC-18-0332. Epub 2019 Jan 1. PMID: 30667365.
23. Carlsen EA, **Fazio N**, Granberg D, Grozinsky-Glasberg S, Ahmadzadehfar H, Grana CM, Zandee WT, Cwikla J, Walter MA, Oturai PS, Rinke A, Weaver A, Frilling A, Gritti S, Arveschoug AK, Meirovitz A, Knigge U, Sorbye H. Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study. *Endocr Relat Cancer*. 2019 Feb 1;26(2):227-239. doi: 10.1530/ERC-18-0424. PMID: 30540557.
24. Jensen RT, Bodei L, Capdevila J, Couvelard A, Falconi M, Glasberg S, Kloppel G, Lamberts S, Peeters M, Rindi G, Rinke A, Rothmund M, Sundin A, Welin S, **Fazio N**; The ENETS 2016 Munich Advisory Board Participants; ENETS 2016 Munich Advisory Board Participants. Unmet Needs in Functional and Nonfunctional Pancreatic Neuroendocrine Neoplasms. *Neuroendocrinology*. 2019;108(1):26-36. doi: 10.1159/000494258. Epub 2018 Oct 3. PMID: 30282083.
25. Raj N, **Fazio N**, Strosberg J. Biology and Systemic Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors. *Am Soc Clin Oncol Educ Book*. 2018 May 23;38:292-299. doi: 10.1200/EDBK_200893. PMID: 30231344.
26. Raymond E, Kulke MH, Qin S, Yu X, Schenker M, Cubillo A, Lou W, Tomasek J, Thiis-Evensen E, Xu JM, Croitoru AE, Khasraw M, Sedlackova E, Borbath I, Ruff P, Oberstein PE, Ito T, Jia L, Hammel P, Shen L, Shrikhande SV, Shen Y, Sufliarsky J, Khan GN, Morizane C, Galdy S, Khosravan R, Fernandez KC, Rosbrook B, **Fazio N**. Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumours. *Neuroendocrinology*. 2018;107(3):237-245. doi: 10.1159/000491999. Epub 2018 Jul 10. PMID: 29991024.
27. **Fazio N**, Buzzoni R, Delle Fave G, Tesselaar ME, Wolin E, Van Cutsem E, Tomassetti P, Strosberg J, Voi M, Bubuteishvili-Pacaud L, Ridolfi A, Herbst F, Tomasek J, Singh S, Pavel M, Kulke MH, Valle JW, Yao JC. Everolimus in advanced, progressive, well-differentiated, non-functional neuroendocrine tumors: RADIANT-4 lung subgroup analysis. *Cancer Sci*. 2018 Jan;109(1):174-181. doi: 10.1111/cas.13427. Epub 2017 Nov 9. PMID: 29055056; PMCID: PMC5765303.
28. **Fazio N**, Milione M. Heterogeneity of grade 3 gastroenteropancreatic neuroendocrine carcinomas: New insights and treatment implications. *Cancer Treat Rev*. 2016 Nov;50:61-67. doi: 10.1016/j.ctrv.2016.08.006. Epub 2016 Aug 28. PMID:27636009.
29. **Fazio N**, Buzzoni R, Baudin E, Antonuzzo L, Hubner RA, Lahner H, DE Herder WW, Raderer M, Teulé A, Capdevila J, Libutti SK, Kulke MH, Shah M, Dey D, Turri S, Aimone P, Massacesi C, Verslype C. A Phase II Study of BEZ235 in Patients with Everolimus-resistant, Advanced Pancreatic Neuroendocrine Tumours. *Anticancer Res*. 2016 Feb;36(2):713-9. PMID: 26851029; PMCID: PMC5076549.
30. Spada F, Antonuzzo L, Marconcini R, Radice D, Antonuzzo A, Ricci S, Di Costanzo F, Fontana A, Gelsomino F, Luppi G, Nobili E, Galdy S, Cella CA, Sonzogni A, Pisa E, Barberis M, **Fazio N**. Oxaliplatin-Based Chemotherapy in Advanced Neuroendocrine Tumors: Clinical Outcomes and Preliminary Correlation with Biological Factors. *Neuroendocrinology*. 2016;103(6):806-14. doi: 10.1159/000444087. Epub 2016 Jan 21. PMID: 26789262.
31. **Fazio N**, Biffi R, Maibach R, Hayoz S, Thierstein S, Brauchli P, Bernhard J, Stupp R, Andreoni B, Renne G, Crosta C, Morant R, Chiappa A, Luca F, Zampino MG, Huber O, Goldhirsch A, de Braud F, Roth AD; Swiss Group for Clinical Cancer Research SAKK; European Institute of

- Oncology, Milan, Italy. Preoperative versus postoperative docetaxel-cisplatin-fluorouracil (TCF) chemotherapy in locally advanced resectable gastric carcinoma: 10-year follow-up of the SAKK 43/99 phase III trial. *Ann Oncol.* 2016 Apr;27(4):668-73. doi: 10.1093/annonc/mdv620. Epub 2015 Dec 27. PMID: 26712905.
32. Yao JC, **Fazio N**, Singh S, Buzzoni R, Carnaghi C, Wolin E, Tomasek J, Raderer M, Lahner H, Voi M, Pacaud LB, Rouyrre N, Sachs C, Valle JW, Fave GD, Van Cutsem E, Tesselar M, Shimada Y, Oh DY, Strosberg J, Kulke MH, Pavel ME; RAD001 in Advanced Neuroendocrine Tumours, Fourth Trial (RADIANT-4) Study Group. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo- controlled, phase 3 study. *Lancet.* 2016 Mar 5;387(10022):968-977. doi:10.1016/S0140-6736(15)00817-X. Epub 2015 Dec 17. PMID: 26703889; PMCID:PMC6063317.
 33. Koumariou A, Kaltsas G, Kulke MH, Oberg K, Strosberg JR, Spada F, Galdy S, Barberis M, Fumagalli C, Berruti A, **Fazio N**. Temozolomide in Advanced Neuroendocrine Neoplasms: Pharmacological and Clinical Aspects. *Neuroendocrinology.* 2015;101(4):274-88. doi: 10.1159/000430816. Epub 2015 Apr 29. PMID: 25924937.
 34. **Fazio N**, Granberg D, Grossman A, Saletan S, Klimovsky J, Panneerselvam A, Wolin EM. Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3, randomized, placebo-controlled RADIANT-2 study. *Chest.* 2013 Apr;143(4):955-962. doi: 10.1378/chest.12-1108. PMID: 23187897.
 35. **Fazio N**, Luca F, Monfardini L, Pelosi G, Bodei L, Lorizzo K, Di Meglio G, Gibelli B, Ravizza D, Bonomo G, Grana CM, Baio S, Squadroni M, Paganelli G, de Braud F. Right pelvic mass in a patient with a radically resected carcinoid of the appendix. *Gut.* 2009 Sep;58(9):1200, 1259. doi: 10.1136/gut.2008.167452.PMID: 19671553.
 36. **Fazio N**, Dettori M, Lorizzo K. Temsirolimus for advanced renal-cell carcinoma. *N Engl J Med.* 2007 Sep 6;357(10):1050; author reply 1050-1. doi: 10.1056/NEJMc071868. PMID: 17804854.
 37. Roth AD, **Fazio N**, Stupp R, Falk S, Bernhard J, Saletti P, Köberle D, Borner MM, Rufibach K, Maibach R, Wernli M, Leslie M, Glynne-Jones R, Widmer L, Seymour M, de Braud F; Swiss Group for Clinical Cancer Research. Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research. *J Clin Oncol.* 2007 Aug 1;25(22):3217-23. doi: 10.1200/JCO.2006.08.0135. PMID: 17664469.
 38. **Fazio N**, de Braud F, Delle Fave G, Öberg K. Interferon-alpha and somatostatin analog in patients with gastroenteropancreatic neuroendocrine carcinoma: single agent or combination? *Ann Oncol.* 2007 Jan;18(1):13-19. doi:10.1093/annonc/mdl144. Epub 2006 Jun 23. PMID: 16798833.
 39. **Fazio N**, Spaggiari L, Pelosi G, Presicci F, Preda L. Langerhans' cell histiocytosis. *Lancet.* 2005 Feb 12-18;365(9459):598. doi: 10.1016/S0140-6736(05)17910-0. PMID: 15708104.
 40. **Fazio N**, Orsi F, Grasso RF, Ferretti G, Medici M, Rocca A, Zampino G, Curigliano G, De Pas T, Colleoni M, Bonomo G, Marrocco E, Lunghi L, De Braud F. Hepatic intra-arterial chemotherapy using a percutaneous catheter in pretreated patients with metastatic colorectal carcinoma. *Anticancer Res.* 2003 Nov- Dec;23(6D):5023-30. PMID: 14981962.

Congresses

Main presentations:

- 2020: **ESMO annual congress, Chair of the ESMO Track for NET**
- 2018: **ASCO annual meeting, Invited speaker at the NET educational session**
- 2018-2022: **ESMO Annual Congress, Invited speaker and chair at the NET educational session**
- 2017: **ESMO ASIA annual Congress, Member of Scientific Committee for the "Gastrointestinal tumors" Track**

Milan, 25-04-2024

